Drug Profile
Ruxotemitide - Lytix Biopharma
Alternative Names: Cancer-vaccine-Lytix-Biopharma; LTX-315; Oncopore; VP-315; VP-LTX-315Latest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator Lytix Biopharma
- Developer Lytix Biopharma; Verrica Pharmaceuticals
- Class Adjuvants; Amides; Amines; Antineoplastics; Benzyl compounds; Butylamines; Immunotherapies; Indoles; Peptides
- Mechanism of Action Cell membrane structure modulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Basal cell cancer; Malignant melanoma; Soft tissue sarcoma
- Phase I/II Solid tumours
- No development reported Carcinoma; Triple negative breast cancer
Most Recent Events
- 31 Dec 2023 Lytix Biopharma files for patent protection with Patent Corporation Treaty (PCT) for Ruxotemitide (LTX 315)
- 31 Dec 2023 Lytix Biopharma files an clinical trial application with the regulatory authorities in stage III-IV melanoma
- 23 Oct 2023 Updated efficacy and safety data from the phase II ATLAS-IT-05 trial in Malignant melanoma released by Lytix Biopharma